The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

The worlds of biotechnology and cryptocurrency are colliding in unprecedented ways. Once viewed as niche markets, digital ...

The Dow Jones index fell but Amazon surged on deal with OpenAI. Kimberly-Clark plunged on the stock market today. Palantir ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

"This technology could be important for in vivo delivery," meaning ... The COVID-19 vaccines manufactured by Pfizer-BioNTech ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.